The University of Texas MD Anderson Cancer Center

What The University of Texas MD Anderson Cancer Center does

The University of Texas MD Anderson Cancer Center is a public academic medical center and one of 57 NCI-designated Comprehensive Cancer Centers, founded in 1941 and headquartered in the Texas Medical Center in Houston. The institution delivers the full spectrum of cancer care — including surgery, chemotherapy, radiation therapy, immunotherapy, CAR T cell therapy, bone marrow transplant, and targeted therapy — across its main campus and eight Greater Houston-area locations (West Houston, League City, Sugar Land, The Woodlands, Bellaire, Bastrop, Northwest Houston, and the Texas Medical Center). It has been ranked #1 in the nation for cancer care by U.S. News & World Report for 36 consecutive years, supports more NCI Specialized Programs of Research Excellence (SPOREs) than any other institution, and runs 1,099 CCSG program members across nine thematic research programs, 16 clinical site disease groups, and 13 full shared resources.

Revenue is generated primarily through patient-care services (diagnostics, treatments, surgeries, clinical trials) reimbursed under standard healthcare insurance models, supplemented by federal research grants (NIH, NCI), philanthropy (including $750M from the Dells and $150M from the Kinder Foundation in 2026), and state appropriations. Distribution is direct-to-consumer via the hospital and clinic network, augmented by the MD Anderson Cancer Network partner-hospital channel and an International Center serving referrals from over 100 countries through IAEA Rays of Hope and direct referrals.

The core technology stack combines clinical operations with proprietary research and AI platforms: the APOLLO longitudinal learning system for patient-data integration; the SOPHiA DDM Platform collaboration for next-generation sequencing analytics; the REDMOD AI system for early pancreatic-cancer detection from CT scans; the Path-IO deep-learning platform for immunotherapy-response prediction in NSCLC; the AI-driven Pan-Cancer Spatial Atlas of Tertiary Lymphoid Structures across 12 cancer types; novel therapies including CD94-targeted CAR T cell therapy, BetaBart radio-theranostic, tile-based radiation therapy (TBRT), HAMMR living-pharmacy platform, and the Institute for Cell Therapy Discovery & Innovation. Education is delivered through the School of Health Professions, graduate medical education, and 1,414 research trainees plus 1,775 clinical residents and fellows. The organization is governed as part of the University of Texas System and operates under NCI Comprehensive Cancer Center designation rather than as a commercial enterprise.

Name

The University of Texas MD Anderson Cancer Center

Legal name

The University of Texas MD Anderson Cancer Center

Website

https://mdanderson.org

Company type

Public

Founded year

1941

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

MD Anderson is a public academic medical center and NCI-designated Comprehensive Cancer Center in Houston that delivers the full spectrum of cancer care, research, and education across nine Greater Houston locations, serving individual cancer patients domestically and patients from over 100 countries internationally.

Ownership category

akta.pro rank

Product category

Cancer Care Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Offices of Physicians (62111)

SIC

Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Radiation Oncology (HLAKAFAC), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)

Keywords

• Cancer treatment services
• Oncology research programs
• Clinical trials oncology
• Cancer prevention screening
• Medical education training

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices9 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales, Others

Revenue model

1. Patient Care Services: MD Anderson generates revenue primarily through patient care services including diagnostic procedures, treatments, surgeries, chemotherapy, radiation therapy, immunotherapy, and clinical trials at its main campus and multiple Houston-area locations.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels5 records

Core offering

MD Anderson is a comprehensive cancer center providing full-spectrum cancer treatment services including surgery, chemotherapy, radiation therapy (including proton therapy and tile-based radiation), immunotherapy, CAR T cell therapy, bone marrow transplantation, and targeted therapy to patients primarily in the Greater Houston area and internationally. The institution simultaneously runs one of the nation's largest oncology research portfolios spanning basic, translational, and clinical research, along with degree-granting schools and graduate medical education programs for oncology trainees.

Product overview

MD Anderson Cancer Center is a comprehensive cancer center offering a unified portfolio of clinical care services, research programs, and educational offerings. The institution provides full-spectrum cancer treatment including surgery, chemotherapy, radiation, immunotherapy, cellular therapy, CAR T, and targeted therapy through specialized care centers. Research infrastructure includes the Institute for Cell Therapy Discovery & Innovation, the Institute for Data Science in Oncology (IDSO), and the APOLLO adaptive learning platform. AI-powered offerings include the SOPHiA DDM™ Platform NGS test (co-developed with SOPHiA GENETICS), REDMOD AI for early pancreatic cancer detection, and Path-IO for immunotherapy response prediction. Additional programs include the Rare Tumor Initiative, Tumor Measurement Initiative, Program for T Cell Therapy, and MDACC Epigenomics Therapy Initiative (METI). The institution maintains data resources including the Rareview cBio Portal and Cancer InFocus visualization tools.

Differentiator

Problem solved

Functional benefit

Products and services

• Comprehensive Cancer Care Services Full spectrum of cancer treatment including surgery, chemotherapy, radiation therapy, immunotherapy, cellular therapy, CAR T cell therapy, bone marrow transplant, targeted therapy, and hormone therapy delivered at the main Texas Medical Center campus and Greater Houston area locations.
• Clinical Trials Program Hundreds of oncology clinical trials testing new treatments for both common and rare cancers, providing patients access to promising investigational therapies not available elsewhere, including participation in FDA real-time clinical trial programs.
• Specialized Cancer Care Centers and Clinics Disease-specific multidisciplinary care centers including the Leukemia Center, Lymphoma & Myeloma Center, Stem Cell Transplantation Center, Colorectal Center, Brain Metastases Clinic, and other specialized cancer care clinics.
• Cancer Prevention and Screening Services Risk assessment, screening, and diagnostic services through the Lyda Hill Cancer Prevention Center, including mammograms, cervical, colorectal, endometrial, liver, and lung cancer screenings, genetic testing, counseling, and management of hereditary cancer syndromes.
• Cancer Diagnostics and Pathology Comprehensive diagnostic services including imaging, laboratory testing, genomic testing, pathology review, and second opinion pathology services supporting cancer diagnosis and treatment planning.
• Oncology Education and Training Programs Degree-granting schools (School of Health Professions, MD Anderson UTHealth Houston Graduate School), graduate medical education, research training, postdoctoral training, and continuing professional education programs for medical professionals and trainees.
• International Patient Services International Center serving patients from over 100 countries with coordinated cancer care referrals, language services, and dedicated international patient support infrastructure.
• Second Opinion Services Formal second opinion appointments providing pathology review and clinical consultation for patients seeking expert diagnostic and treatment guidance from MD Anderson specialists.
• Supportive Care Services Palliative care, rehabilitation, and integrative medicine programs supporting cancer patients through treatment including the Supportive Care Center and Texas Community Bus Rounds outreach program.

Quantifiable outcome

• Tile-based radiation therapy (TBRT) reduced tumor recurrence rates to 1.3% compared to 15.4% with standard stereotactic radiation therapy, with median overall survival more than doubled to 42.5 months from 17.6 months
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability13 records

Feature6 records

Partnerships

20 partnerships are on record, tiered major, core and strategic.

• QIMR BerghofermajorStrategic or Co-development Partner · 22 June 2026Strategic partnership to strengthen international collaboration in cell and gene therapy research, translation, workforce development, and advanced manufacturing through the CTMC Global Network Alliance. Combines QIMR Berghofer's translational research and advanced therapeutics manufacturing capabilities with CTMC's model for cell therapy development.
• CTMC (Cell Therapy Manufacturing Center)coreStrategic or Co-development Partner · 22 June 2026Collaboration on cell therapy development, manufacturing, regulatory strategy, and clinical translation. Partnership also supports NextGen, Australia's Centre for Cell and Gene Therapy Innovation and Manufacturing.
• Delphi DiagnosticsstrategicStrategic or Co-development Partner · 22 June 2026Publication collaboration validating Delphi's Endocrine Activity Index (EAI) test for predicting benefit from weekly paclitaxel in HR+/HER2- breast cancer patients based on GEICAM/9906 clinical trial analysis.
• IAEA (International Atomic Energy Agency)majorStrategic or Co-development Partner · 20 June 2026Partnership through IAEA's Rays of Hope cancer care initiative, with MD Anderson helping deliver training, technology, and expertise to countries with limited access to radiotherapy and medical imaging services. Over 100 countries have requested support.
• IBA (Ion Beam Applications S.A.)strategicStrategic or Co-development Partner · 10 June 2026Sponsored research agreement to generate clinical and economic evidence on the cost-effectiveness of proton beam therapy compared to other treatment modalities. Research led by Dr. Matthew Ning and Dr. Iakovos Toumazis from MD Anderson's Institute for Data Science in Oncology.
• Ochsner HealthstrategicStrategic or Co-development Partner · 29 May 2026Strategic integration through partnership providing Ochsner Health access to early-phase clinical trials from UT MD Anderson Cancer Center as part of their 23rd Annual Research Week.
• Banner HealthstrategicStrategic or Co-development Partner · 26 May 2026Partnership with Banner Health's research enterprise conducting $80.5 million in research, providing MD Anderson access to clinical trial network and collaborative research opportunities.
• Rice UniversitystrategicStrategic or Co-development Partner · 12 May 2026Joint research partnership on AVB-001, an implantable cell-based therapy delivering interleukin-2 directly to ovarian cancer patients, reporting first-in-human Phase I trial results.
• TriSalus Life SciencesstrategicStrategic or Co-development Partner · 4 May 2026Expansion of existing collaboration for PREDICTT clinical trial evaluating Pressure-Enabled Drug Delivery (PEDD) technology with TriNav Infusion System in patients with liver tumors undergoing Y90 radioembolization therapy.
• Genprex Inc.strategicStrategic or Co-development Partner · 21 April 2026Sponsored Research Agreement to study TROP2 and PTEN biomarkers that may predict patient response to Reqorsa Gene Therapy for non-small cell and small cell lung cancer treatment. Aims to refine patient selection strategies for Acclaim-1 and Acclaim-3 clinical trials.
• DuracytestrategicStrategic or Co-development Partner · 15 April 2026Technology licensing partnership for Duracyte's 'living pharmacy' platform HAMMR. MD Anderson will conduct Phase I clinical trials for recurrent ovarian cancer patients, with Duracyte backed by over $100 million in research funding from DARPA, ARPA-H, NIH, and Gates Foundation.
• Radiopharm TheranosticscoreStrategic or Co-development Partner · 1 April 2026Partnership through Radiopharm Ventures, LLC for BetaBart, a first-in-class radio-theranostic drug using Lutetium-177 targeting B7-H3 protein, with Phase I/II clinical trial underway.
• BostonGenestrategicStrategic or Co-development Partner · 31 March 2026Collaboration on FEASY study published in Cancer Discovery, demonstrating that RNA-based multiomic analysis identified new therapeutic targets for antibody-drug conjugates in patients with advanced solid tumors.
• Cancer Vaccine CoalitionstrategicStrategic or Co-development Partner · 31 March 2026$1 million grant for Phase II INTERCEPT-HER2 clinical trial using blood tests to detect circulating tumor DNA in HER2+ breast cancer patients and therapeutic vaccines to prevent recurrence.
• Io TherapeuticsstrategicStrategic or Co-development Partner · 11 March 2026Collaboration on RXR agonist compound IRX4204 for breast cancer prevention, published in Cancer Prevention Research, demonstrating prevention of ER-negative and triple-negative breast tumor formation.
• PranaX CorpstrategicOEM/ Whitelabel/ Licensing Partner · 2 February 2026Technology licensing partnership for exosome-based regenerative biologics technology developed at MD Anderson and tested in Phase I clinical trial for pancreatic cancer.
• SOPHiA GENETICScoreStrategic or Co-development Partner · 7 January 2026Strategic collaboration to co-develop a next-generation sequencing oncology test built on SOPHiA DDM Platform and launch joint research programs focused on tumor evolution characterization, genomic testing reliability, and patient clinical trial matching.
• Pulse BiosciencesstrategicStrategic or Co-development Partner · 9 December 2025Research collaboration to evaluate nPulse technology for treating thyroid cancers, with planned clinical study for papillary thyroid microcarcinoma and preclinical studies on anaplastic thyroid carcinoma.
• Lirum TherapeuticsstrategicStrategic or Co-development Partner · 20 October 2025RAPID platform clinical trial collaboration for treating relapsed/refractory Ewing Sarcoma and DSRCT in adolescent and young adult patients, with MD Anderson as trial lead.
• TheolyticsstrategicStrategic or Co-development Partner · 13 October 2025US trial exploring intraperitoneal delivery of THEO-260 for platinum-resistant ovarian cancer in collaboration with Theolytics' OCTOPOD-IV trial.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Massachusetts General Hospital / Mass General Brigham: Harvard-affiliated multi-specialty academic system with a large cancer center. Comparable in proton therapy, research output, and clinical-trial breadth, though oncology is part of a wider portfolio.
• Stanford Medicine / Stanford Cancer Institute: Academic medical center with an NCI-designated cancer institute. Overlaps heavily on AI-driven pathology, genomics, immunotherapy, and clinical-trial innovation within a broader health system.
• Mayo Clinic: Multi-specialty academic health system with one of the largest U.S. cancer programs, co-developer with MD Anderson of REDMOD AI. Overlaps in research depth, brand reputation, and proton therapy but spans all specialties.
• Cleveland Clinic: Large multi-specialty academic health system with a major cancer institute (Taussig). Comparable in scale, brand, and clinical-trial infrastructure but broader than oncology-only.

Direct peers

• City of Hope: NCI Comprehensive Cancer Center in Southern California with a strong cell therapy and bone-marrow transplant franchise. Comparable size and direct overlap in CAR T, hematologic malignancies, and academic-industry partnerships.
• Fred Hutchinson Cancer Center: NCI Comprehensive Cancer Center in Seattle, originally founded as a research center, now integrated with UW Medicine. Direct peer in bone-marrow transplantation, cell therapy, and immunotherapy research.
• Dana-Farber Cancer Institute: NCI Comprehensive Cancer Center affiliated with Harvard/Brigham and Women's, focused exclusively on adult and pediatric oncology. Directly comparable in clinical trials volume, research output, and translational pipeline.
• H. Lee Moffitt Cancer Center & Research Institute: NCI Comprehensive Cancer Center in Tampa, FL, focused solely on oncology. Closely comparable mission (cancer-only specialty hospital + research institute), scale, and patient mix.
• Memorial Sloan Kettering Cancer Center: Largest U.S. cancer-only specialty hospital and NCI Comprehensive Cancer Center. Direct peer on every dimension: inpatient oncology, translational research, NCI SPOREs, CAR T development, and U.S. News cancer-care rankings.
• Johns Hopkins Medicine / Sidney Kimmel Comprehensive Cancer Center: NCI Comprehensive Cancer Center within Johns Hopkins, with overlapping strengths in translational research, CAR T, immunotherapy, and rare cancers. Same scale and academic medical-center operating model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mdandersonnews
• Facebookfacebook.com/MDAnderson
• LinkedInlinkedin.com/company/mdandersoncancercenter

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The University of Texas MD Anderson Cancer Center